Price Alert

Ionis Pharmaceuticals Inc... (IONS)

NASDAQ: IONS · Real-Time Price · USD

59.35

-1.14 (-1.88%)

At close: Sep 04, 2025, 3:59 PM

59.59

0.40%

After-hours: Sep 04, 2025, 07:44 PM EDT

Ionis Pharmaceuticals Statistics

Share Statistics

Ionis Pharmaceuticals has 159.39M shares outstanding. The number of shares has increased by 0.92% in one year.

Shares Outstanding	159.39M
Shares Change (YoY)	0.92%
Shares Change (QoQ)	0.12%
Owned by Institutions (%)	99.99%
Shares Floating	158.08M
Failed to Deliver (FTD) Shares	1,190
FTD / Avg. Volume	0.05%

Short Selling Information

The latest short interest is 10.79M, so 6.77% of the outstanding shares have been sold short.

Short Interest	10.79M
Short % of Shares Out	6.77%
Short % of Float	8.98%
Short Ratio (days to cover)	5.01

Valuation Ratios

The PE ratio is -11.52 and the forward PE ratio is -19.26. Ionis Pharmaceuticals's PEG ratio is -0.61.

PE Ratio	-11.52
Forward PE	-19.26
PS Ratio	7.41
Forward PS	10.3
PB Ratio	8.88
P/FCF Ratio	-9.57
PEG Ratio	-0.61

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Ionis Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.47, with a Debt / Equity ratio of 2.41.

Current Ratio	8.47
Quick Ratio	8.43
Debt / Equity	2.41
Debt / EBITDA	-2.98
Debt / FCF	-2.59
Interest Coverage	-5.25

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$659.62K
Profits Per Employee	$-424.6K
Employee Count	1,069
Asset Turnover	0.23
Inventory Turnover	0.9

Taxes

Income Tax	-6.17M
Effective Tax Rate	1.34%

Stock Price Statistics

The stock price has increased by 23.26% in the last 52 weeks. The beta is 0.28, so Ionis Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.28
52-Week Price Change	23.26%
50-Day Moving Average	43.1
200-Day Moving Average	35.73
Relative Strength Index (RSI)	81.99
Average Volume (20 Days)	2,300,779

Income Statement

In the last 12 months, Ionis Pharmaceuticals had revenue of 705.14M and earned -453.9M in profits. Earnings per share was -3.04.

Revenue	705.14M
Gross Profit	693.92M
Operating Income	-475.08M
Net Income	-453.9M
EBITDA	-475.08M
EBIT	-477.06M
Earnings Per Share (EPS)	-3.04

Full Income Statement

Balance Sheet

The company has 242.08M in cash and 1.42B in debt, giving a net cash position of -1.17B.

Cash & Cash Equivalents	242.08M
Total Debt	1.42B
Net Cash	-1.17B
Retained Earnings	-2.25B
Total Assets	2.99B
Working Capital	1.68B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -500.95M and capital expenditures -45.28M, giving a free cash flow of -546.23M.

Operating Cash Flow	-500.95M
Capital Expenditures	-45.28M
Free Cash Flow	-546.23M
FCF Per Share	-3.65

Full Cash Flow Statement

Margins

Gross margin is 98.41%, with operating and profit margins of -67.37% and -64.37%.

Gross Margin	98.41%
Operating Margin	-67.37%
Pretax Margin	-65.25%
Profit Margin	-64.37%
EBITDA Margin	-67.37%
EBIT Margin	-67.37%
FCF Margin	-77.46%

Dividends & Yields

IONS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for IONS is $67.5, which is 13.7% higher than the current price. The consensus rating is "Buy".

Price Target	$67.5
Price Target Difference	13.7%
Analyst Consensus	Buy
Analyst Count	16

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	1.42
Piotroski F-Score	3